Oral tongue squamous cell carcinomas (OTSCC) are a homogenous group of 21 tumors characterized by aggressive behavior, early spread to lymph nodes and a 22 higher rate of regional failure. Additionally, the incidence of OTSCC among younger 23 population (<50yrs) is on a rise; many of who lack the typical associated risk factors 24 of alcohol and/or tobacco exposure. We present data on SNVs, indels, regions with 25 LOH, and CNVs from fifty-paired oral tongue primary tumors and link the significant 26 somatic variants with clinical parameters, epidemiological factors including HPV 27 infection and tumor recurrence. Apart from the frequent somatic variants harbored in 28 TP53, CASP8, RASA1, NOTCH and CDKN2A genes, significant amplifications and/or 29 deletions were detected in chromosomes 6-9, and 11 in the tumors. Variants in CASP8 30 and CDKN2A were mutually exclusive. CDKN2A, PIK3CA, RASA1 and DMD 31 variants were exclusively linked to smoking, chewing, HPV infection and tumor 32 stage. We also performed whole-genome gene expression study that identified matrix 33 metalloproteases to be highly expressed in tumors and linked pathways involving 34 arachidonic acid and NF-κ-B to habits and distant metastasis, respectively. Functional 35 knockdown studies in cell lines demonstrated the role of CASP8 in HPV-negative 36 OTSCC cell line. Finally, we identified a 38-gene minimal signature that predicts 37 tumor recurrence using an ensemble machine learning method. Taken together, this 38 study links molecular signatures to various clinical and epidemiological factors in a 39 homogeneous tumor population with a relatively high HPV prevalence.
Introduction 45
Squamous cell carcinomas of head and neck (HNSCC) are the sixth leading 46 cause of cancer worldwide [1] . Tumors of head and neck region are heterogeneous in 47 nature with different incidences, mortalities and prognosis for different subsites and stage had no significant impact on the distribution of these nucleotides (Additional 155 file 5). We used the workflow described in the Methods section to identify somatic 156 mutations and indels in tumor samples following which we used three functional 157 tools, IntOGen [19] , MutSigCV [21] and MuSiC2 [22] for variant interpretations 158 (Additional file 6). In order to identify genes harboring significant variants, we used 159 the intersection of these tools, following the criteria that the somatic variants be 160 callable in the matched control sample and present in a single sequencing read in the 161 control sample. This resulted in a final list of 19 cancer-associated genes ( Figure 1C) , 162 which were divided into three categories with varying mutation frequencies ( Figure   163 1D). The three frequency tiers were ≥ 30% (TP53), 6-30% (RASA1, CASP8 and 164 CDKN2A) and 2-5% (NOTCH1, NOTCH2, DMD and PIK3CA were prominent 165 among them). 166 Next, we looked for mutual exclusivity of finding somatic variants in the 167 genes and found that many of these genes harbor variants in a mutually exclusive 168 manner across samples ( Figure 1E ), suggesting the possibility that there might be 169 some common pathway(s) involved in the development of OTSCC. We observed 170 mutual exclusivity among somatic variants in NOTCH1 and NOTCH2 genes, and 171 expanded this finding to identifying 15 such mutually exclusive sets ( Figure 1E ). 172 Among them, CDKN2A, HLA-A and TTK form a mutually exclusive set with TP53; 173 RASA1, OBSCN, HLA-A, AJUBA and TTK are mutually exclusive with either 174 NOTCH1 alone, or NOTCH2 and ANK3 together; NOTCH1, NOTCH2, HLA-A, 175 AJUBA, ANK3, TTK, MLL2, ING1 or KEAP1, are mutually exclusive with CASP8 176 alone, or FAT1 and DMD together; FAT1, HLA-A, AJUBA, ANK3, TTK, MLL2, ING1 177 or KEAP1, are mutually exclusive with PIK3CA or DMD or NOTCH1 and OBSCN, or 178 CDKN2A and OBSCN; U2AF1, MLL2 and TTK form a small mutually exclusive set.
We juxtaposed the positions of the somatic variants from final list of all 19 genes 180 (Additional file 7) detected in OTSCC against those found in the TCGA data using 181 the cBioPortal. We found that the somatic variants in OTSCC were in the same 182 domains where mutations were observed earlier in many of the genes (Additional file 183 7).
184
Copy Number Variation (CNV) analyses using data from the whole-genome 185 SNP genotyping arrays revealed a large chunk of chromosome 9, bearing cancer-186 associated genes like CDKN2A, NF1 and MRPL4, to be affected in about 17% of the 187 tumors ( Figure 1F and Additional file 8). We found several CNVs of short stretches 188 (in low kb range) within chromosomes 6-8, 11, 17 and X in many tumors.
190
Linking habits, HPV infection, nodal status, tumor grade and recurrence, with genes 191 harboring somatic variants and the associated pathways 192 We further classified the 19 cancer-associated genes from the previous 193 analyses and linked those with habits, clinical parameters and HPV infection. Among 194 the genes harboring significant somatic variants, we found CDKN2A to be mutated 195 only in the never smokers and past smokers, PIK3CA to be mutated only in the 196 smokers, and TP53 to be mutated at a 20% greater frequency in the smokers, CASP8 197 has a 12% greater frequency in those that consumed alcohol or chewed tobacco.
198
RASA1 was exclusively mutated only in the non-chewers. (Figure 2A ). HPV-negative (Figure 2A ). We further studied the association of affected cancer-related 205 signaling pathways with habits and clinical parameters, and found that recurrence and 206 HPV infection had the highest impact ( Figure 2B ). The Procaspase-8 activation, 207 Notch, p53 and Wnt signaling pathways were linked most with many of the clinical 208 parameters, HPV infection and habits ( Figure 2B ).
210
Differentially expressed genes in OTSCC 211 Significant (q val ≤ 0.05) differentially expressed genes with a fold change of 212 at least 1.5 revealed a consistent pattern of differential expression across the tumor 213 samples (21 up-and 23 down-regulated genes, Figure 3A and Additional file 9).
214
Genes in PPAR signaling-(e.g., MMP1) and ECM-receptor interaction pathways 215 (LAMC2 and SPP1) were up-regulated and CRNN, APOD, SCARA5 and RERGL were 216 down-regulated in a majority of tumors ( Figure 3A ). Next, we studied the pathways Figure 4C ). Interestingly, we found that 244 the extent of rescue is greater in the HPV-negative cell line compared to the HPV16-245 positive one.
246
Tumor recurrence prediction using random forests 247 After cataloging the significantly altered genes in OTSCC, we wanted to see 248 whether there is a relationship between the altered genes and loco-regional recurrence 249 of tumors and metastasis. In order to do this, we used an ensemble machine learning 250 method implemented by variable elimination using random forests [11] ( Figure 5 ). 251 We used multiple testing correction and the 0.632 bootstrapping method [17] to 252 estimate false positives. We discovered a 38-gene minimal signature that 
288
We applied stringent filtering steps and used multiple annotation tools to come 289 up with a list of 19 cancer-associated genes that harbored somatic variants in OTSCC.
290
Most of these genes were also found in other studies, including the recent TCGA respectively. This is different from what we found in the current study (8%, 4%, 6% 296 and 2% respectively for the same genes). This may partly be attributed to the total 297 number of tumor samples used in different studies but may also be due to a unique 298 pattern of mutations specific to oral tongue subsite. It appears from our study that the 299 latter is the case. For example, in one of the earlier studies [6] involving similar 300 number of patients as in the current study, CASP8 and FAT1 were mutated in 34% 301 and 50% of the patients but we find the frequency to be 8% and 2%, respectively. In 302 some earlier studies, it was not possible to categorize and identify oral tongue-specific 303 variants as the sites were classified under oral cavity [3, 4] . 304 Although the somatic variants discovered from our study appear to be 305 distributed uniformly across the genome, the significant copy number variation events 306 are more concentrated in chromosomes 6-9 and 11 ( Figure 1F and Additional file 8). 307 One of the most important genes harboring somatic mutations discovered in our study 308 is CASP8, the product for which derived from the precursor Procaspase-8. Caspase- In the past, several large sequencing studies have been undertaken in HNSCC
328
[3-5, 7] that contained very few HPV-positive oral tongue patients. Our study is based 329 on a unique patient cohort and attempts to link molecular signature with different 330 clinical and epidemiological parameters. The prevalence of HPV is very high in oral 331 tongue tumors from India, including in our cohort, compared with studies using 332 cohorts elsewhere. We don't see the same high prevalence of HPV in non-oral tongue 333 tumors in oral cavity, for example in buccal tumors, in one of our study (Palve et al., 334 unpublished observation). The exact reason for this high prevalence is not know.
335
Additionally, the HPV positive patients that harbor mutations in TP53 in some of the 336 patient samples is also counter-intuitive owing to the fact that E6 is known to block 337 p53. Although we don't know the reason behind this, there is a possibility that HPV 338 positive tumors harboring TP53 mutations represent a unique class of tumors and it 339 will be interesting to see if those tumors recur early or late compared to the HPV 340 positive tumors that have wild type p53 function. Therefore, this study is unique in 341 that respect.
342
Identifying signature for tumor recurrence prospectively in primary tumors 343 may add significant advantage to disease management. In order to do this, we used a 344 machine learning method using the molecular changes identified in this study, in three 345 batches of primary tumors; non-recurring, loco-regionally recurring and tumors with 346 distant metastasis. We identified a 38-gene signature to be significantly distinguishing in out study, however, needs to be validated in a much larger cohort in the future to 353 achieve its true potential as a prognostic panel in OTSCC. 354 Finally, we were keen to see if the current study leads to finding novel drug 355 candidates in OTSCC. We based our assumption on the fact that genome-wide 356 somatic variant discovery in tumors may give rise to possibilities of finding novel 357 drug targets/candidates or may led us to use existing drugs prescribed for other 358 indications. In an attempt to identify if any of the significantly altered genes found in 359 the current study could potentially act as drug targets, we screened for available drugs 360 against them. We found drugs against three targets out of which two have undergone 361 at least one clinical trial (Additional file 13). 
